Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 8
Submit an article Journal homepage
1,712
Views
4
CrossRef citations to date
0
Altmetric
Author's View

Combination of adoptive cell transfer, anti-PD-L1 and anti-LAG-3 antibodies for the treatment of recurrent tumors

Better with more

Stephen R Goding Department of Pathology; University of Maryland School of Medicine; Baltimore, MD USA
,
Kyle A Wilson Department of Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MD USA
&
Paul Andrew Antony Department of Pathology; University of Maryland School of Medicine; Baltimore, MD USA; Department of Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MD USA; Tumor Immunology and Immunotherapy Program; University of Maryland Cancer Center; Baltimore, MD USACorrespondence[email protected]
Article: e25050 | Received 15 May 2013, Accepted 15 May 2013, Published online: 20 May 2013

References

  • Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637 - 50; http://dx.doi.org/10.1084/jem.20091918; PMID: 20156971
  • Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651 - 67; http://dx.doi.org/10.1084/jem.20091921; PMID: 20156973
  • Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412 - 6; http://dx.doi.org/10.1038/nature11538; PMID: 23051752
  • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207 - 12; http://dx.doi.org/10.1016/j.coi.2011.12.009; PMID: 22236695
  • Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, et al. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J Immunol 2012; 189:767 - 76; http://dx.doi.org/10.4049/jimmunol.1103822; PMID: 22723522
  • Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, et al. Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma. J Immunol 2013; 190:4899 - 909; http://dx.doi.org/10.4049/jimmunol.1300271; PMID: 23536636
  • Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:27ra37; http://dx.doi.org/10.1126/scitranslmed.3003689; PMID: 22461641
  • Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10:29 - 37; http://dx.doi.org/10.1038/ni.1679; PMID: 19043418
  • Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol 2012; 13:188 - 95; http://dx.doi.org/10.1038/ni.2180; PMID: 22157630

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.